KR20190140128A - Extract of angelica gigas cornucopia containing decursin for improvement of menopausal bone health - Google Patents

Abstract

The present invention relates to a use of an Angelica gigas spirit extract, containing decursin. More specifically, the present invention discloses a method for administering an Angelica gigas spirit extract having an effect of alleviating osteoporosis. Specifically, the present invention is characterized in oral administration of the Angelica gigas spirit extract for 62.5 to 250mg/kg as the method for administering the Angelica gigas spirit extract.

Description

EXTRACT OF ANGELICA GIGAS CORNUCOPIA CONTAINING DECURSIN FOR IMPROVEMENT OF MENOPAUSAL BONE HEALTH}

The present invention relates to the use of Angelica gigas extract, containing the duckin, and more particularly, to a method for administering Angelica gigas extract, which has an effect of improving osteoporosis.

It is called menopause, including the transition period, menopause, and postmenopausal period before menopause. During this period, the level of female hormone estrogen decreases and hormones change.

Various menopausal symptoms occur with these hormone changes, and there may be differences in rectification, severity, and duration of symptoms according to the individual.However, the most common menopausal symptoms are vaginal dryness, which is a genitourinary symptom, and facial flushing, which is a symptom of vasomotor movement. Menopausal women are the leading cause of hospital visits.

In addition, decreased secretion of female hormone estrogen during menopause is a major cause of osteoporosis.

Osteoporosis is a metabolic disease in which bone mass is reduced and bone microstructural changes are easily fractured even with small impacts. Estrogen deficiency in menopause is known to accelerate bone loss, and estrogen therapy reduces the risk of osteoporotic fractures. Known.

According to the 2008-2011 National Health and Nutrition Examination Survey, the prevalence of osteoporosis in Koreans was 46.5% for men and 48.7% for women in osteoporosis, and osteoporosis prevalence was 7.3% for men and women over 50 years. 38%.

In addition, Koreans were found to have weaker bones than Americans and Japanese, and the same survey analyzed bone mineral density of hip, femur, and lumbar spine of Koreans, Japanese, and Americans (Hispanic, Caucasian, Black) over 10 years old. appear.

The prevalence of osteoporosis as described above is 5 times higher than that of men because of the 'menopause' that does not secrete female hormones, it is generally known that bone loss by 3% every year for five years immediately after menopause. After five years, they decrease by 1% every year, and by 60 years of age, by 20%, by 80 years of age, by 40% of the total bone volume, the risk of fracture is greatly increased.

On the other hand, the extract of Angelica gigas, which contains Angelica as the main raw material, contains high amounts of functional ingredients decursin and decursinol angelate, and functional compounds decursin improve cognitive function, anti-inflammatory, Various pharmacological effects such as analgesic, joint, and health are known, and the Angelica Angelica extract is the main export product of the present applicant, and the main ingredient is Pangchang of Pyeongchang, Korea.

Dercininol, Dercinin and Dercininol Angelate, known as active ingredients in Angelica gigas, are present in trace amounts in Chinese Angelica and Japanese Angelica gigas, but are present in large amounts in Korean Angelica gigas, and cannot be replaced with cheap Chinese raw materials. It is a raw material that can develop various functional foods according to the manufacturing method because the ingredients extracted according to the solvent are clear and accordingly the efficacy is different.

Functional raw materials related to menopausal women's health include pomegranate extracts and concentrates such as white sorghum, walnut fruit extracts, and pomegranate concentrates.

[Patent Document 0001] Published Patent 10-2002-0078850 (2002.10.19.) [Patent Document 0002] Registered Patent 10-0995891 (2010.11.16.) [Patent Document 0003] Registered Patent 10-1645589 (2016.07.29.) [Patent Document 0004] Published Patent 10-2005-0087946 (2005.09.01.)

The present invention aims to broaden the utilization of Angelica gigas extract of the applicant company having the pharmacological effect as described above, and an object thereof is to provide a method for administering Angelica gigas extract having the effect of preventing and improving osteoporosis after menopause.

The present invention to achieve the object of the present invention as described above,

The present invention provides a method for administering the Angelica gigas extract, oral administration of Angelica gigas extract 62.5mg / kg ~ 250mg / kg once a day.

The present invention was carried out to evaluate whether the duck Angelica alcohol extract containing the duckin is effective in improving menopausal bone health.

After extracting the ovaries of test animals and reducing the secretion of estrogen, the female menopausal model (osteoporosis) was produced, and after the 28-day oral administration of testimonial Angelica extract, the Alaska Angelica extract was released from bone. In addition, it reduced the amount of Ca and was found to have an excellent effect in reducing the amount of DPD and NTX1 excreted in the urine.

In addition, bone mineral density measurements also showed a tendency to increase the various indicators decreased in the Angelica gigas extract.

Therefore, the present invention using the Angelica gigas extract is believed to be effective in improving osteoporosis in female menopause.

1 is an analysis example graph of the present invention

Hereinafter, the present invention will be described in more detail with reference to preferred embodiments. The following description is to aid the understanding and practice of the present invention, but not to limit the present invention thereto. Those skilled in the art will appreciate that various modifications and variations can be made within the spirit of the invention as set forth in the claims below.

EXAMPLE

Purchase and Maintenance of Test Animals

43 SD rats of 5 weeks old were used from Orient Bio (Korea). Animals were kept in an animal test facility maintained at a temperature of 22 to 25 ° C, a relative humidity of 50 to 60%, a contrast cycle of 12 hours, and a roughness of 200 to 300 LUX. Two rats were kept in a polycarbonate box for rats, and animal feed and drinking water were freely consumed.

[Group composition]

After a week of purging, 7 animals underwent gastric surgery, and 36 were ovarian-extracted (OVX) for 14 days. Six animals per group were grouped so that the average body weight was similar among animals without clinical symptoms. The test group included Sham, ovary extraction group (OVX), Angelica gigas extract administration group (OVX + 62.5mg / kg, OVX + 125mg / kg, OVX + 250mg / kg) and estradiol administration group ( OVX + 30 μg / kg) and consisted of six groups.

[Test substance administration]

Gastric surgery group and ovarian extraction group (OVX) were orally administered distilled water once a day for 28 days. The Angelica gigas extract administration group was orally administered once daily for 28 days. Estradiol was formulated in corn oil (Sigma-aldrich, U.S.A.) and administered subcutaneously twice a week for 4 weeks.

[Tissue Collection]

Two days before the last test substance administration, the test animals were placed in a cage with fasting plates for 4 hours and urine was collected and stored at −70 ° C. until used for testing.

Fasting from the last evening of administration of the test substance and tissue was taken out the next morning. Blood is collected from the abdominal aorta using a syringe for blood collection, placed in an SST tube (BD, USA), centrifuged at 3,000 rpm for 20 minutes using a centrifuge (Hanil, Korea), and serum is collected until it is used for testing. Store at 70 ° C.

The uterus was removed, weighed and stored at -70 ° C until used for testing.

The femur was removed from the tissue and placed in 10% neutral formalin to measure microCT.

Blood Biochemical Analysis

Total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride (TG), ALP, Ca, P, AST and ALT were measured on the day of autopsy using a blood biochemical analyzer (Hitich, Japan).

[ELISA]

Estradiol (R & D System, USA), Osteocalcin (Quidel, USA), Deoxypyridinoline (Quidel, USA), and Type I collagen cross-linked telopeptide (NTX1; Abbexa, UK) were performed as manuals for each kit using an ELISA assay kit. .

Femoral Bone Mineral Density Measurement

Bone mineral density was measured by Osong, Korea. Images were taken using a Quantum FX micro-CT (Perkin Elmer, U.S.A.) instrument, and analyzed using bone mineral density, bone microstructure and image analysis using Analyze 12 (Mayo Clinic, U.S.A.).

[Statistical processing]

All data obtained in the experiments were expressed as mean and standard error and were tested using SPSS Version 20.0 Inc. U.S.A. Sham (G1) and OVX (G2) groups performed independent t-tests. Levene's isovariance test was used to confirm isodispersity (significance level: 0.05 on both sides), and t-test results for equality of means were selected according to the results of isovariance test (significance: one-sided 0.05).

One-way analysis of variance (ANOVA) was performed to confirm the significance between each test group (G3 to G5) for OVX group (G2) (multiple test of Dunnett's t-test). Significance level: one-sided 0.05). One-way analysis of variance (ANOVA) was performed (significance level: 0.05) .If significance was observed, Dunnett's t-test was performed to determine the significance between each test group (G1 to G5) for OVX (G2). Multiple tests were performed. The OVX (G2) and estradiol (G6) groups performed independent t-tests. Levene's isovariance test was used to confirm isodispersity (significance level: 0.05 on both sides), and t-test results for equality of means were selected according to the results of isovariance test (significance: one-sided 0.05).

Analysis Example

[Weight and weight gain] (see FIG. 1)

The weight of the Sham group increased steadily from the average of 213.8 g on the day of administration of the test substance to 270.4 g on the end of the administration, showing an increase in weight of 56.6 g.

The body weight of the OVX group steadily increased from 237.4 g on the day of administration of the test substance to 341.4 g on the end of the administration, and showed an increase in body weight of 104.0 g. Compared with the Sham group, there was a statistically significant (p <0.01) increase in body weight during all the test periods, and the weight gain rate was also statistically significant (P <0.01). The ovarian excised female animal gained weight compared to normal animals, and thus it was confirmed that ovarian extraction was normally performed in the test animal.

The body weight of 62.5 mg / kg of Angelica gigas extract increased steadily from 238.4 g on the day of administration of the test substance to 341.7 g on the end of the administration and showed an increase in body weight of 103.3 g. Compared with OVX, there was no difference in body weight and weight gain rate during all trial periods.

 The body weight of 125 mg / kg of Angelica gigas extract increased steadily from 236.0 g on the day of administration to 343.1 g on the end of the administration and showed an increase in body weight of 107.1 g. Compared with OVX, there was no difference in body weight and weight gain rate during all trial periods.

 The body weight of 250 mg / kg of Angelica gigas extract increased steadily from 235.7 g on the day of administration of the test substance to 334.5 g on the end of the administration and showed an increase in weight of 98.7 g. Compared with OVX, there was no difference in body weight and weight gain rate during all trial periods.

 The body weight of the estradiol 30 μg / kg administration group increased steadily from 234.9 g on the day of administration of the test substance to 276.5 g on the end of the administration and showed an increase in body weight of 41.6 g. Compared to OVX, body weight was decreased significantly (p <0.01) and the weight gain rate was also statistically significant (p <0.01) from day 4 after the administration of the test substance.

Analysis of biomarkers related to lipids in blood (see Table 1 below)

[cholesterol]

Total cholesterol, low density cholesterol and high density cholesterol in the Sham group had mean 75.1, 42.7 and 23.5 mg / dL, respectively.

Total cholesterol, low density cholesterol and high density cholesterol in the OVX group were 98.0, 58.7 and 26.1 mg / dL, respectively, compared with the Sham group, and total cholesterol and low density cholesterol were significantly increased.

Total cholesterol, low density cholesterol and high density cholesterol in blood of 62.5 mg / kg group of Angelica gigas extract showed average 94.0, 50.0 and 27.3 mg / dL, respectively, and there was no difference compared to OVX group.

Total cholesterol, low density cholesterol and high density cholesterol in blood of the Angelica gigas extract 125mg / kg group showed an average of 96.9, 45.8 and 28.2mg / dL, respectively, and there was no difference compared to OVX group.

Total cholesterol, low density cholesterol and high density cholesterol in blood of the Angelica gigas extract 250mg / kg group showed an average of 98.6, 56.8 and 29.2mg / dL, respectively, and there was no difference compared to OVX group.

Total cholesterol, low density cholesterol, and high density cholesterol in the estradiol 30μg / kg group showed 90.7, 43.7 and 26.8 mg / dL on average, respectively. There was no significant difference (P <0.05), and high density cholesterol did not show any difference.

Triglycerides

Triglycerides in the blood of the Sham group showed an average of 39.5 mg / dL.

The mean triglyceride level in blood of OVX group was 47.7mg / dL, which was increased compared to Sham group, but there was no statistical significance.

The mean triglycerides in blood of 62.5mg / kg of Angelica gigas extracts were 38.4mg / dL on average and decreased compared to OVX group, but there was no statistical difference.

 The mean triglyceride in blood of 125mg / kg of Angelica gigas extract showed an average of 44.8mg / dL and no difference compared to OVX group.

 The mean triglyceride level in blood of the Angelica gigas extract 250mg / kg group was 36.5mg / dL on average and decreased compared to the OVX group, but there was no statistical difference.

 The average triglyceride in the blood of the estradiol 30μg / kg group was 37.6mg / dL and decreased compared with the OVX group, but there was no statistical difference.

TABLE 1

[Analysis of Biomarkers Related to Bone Health in Blood] (See Table 2 below)

[ALP]

ALP in the blood of the Sham group showed an average of 220.7 IU / L.

The mean ALP of blood in OVX group was 332.3 IU / L, which was statistically significant (P <0.01) compared to Sham group.

Blood ALP of 62.5mg / kg of Angelica gigas extract showed an average of 308.3 IU / L and decreased compared with OVX group, but showed no statistical significance.

The mean ALP in blood of 125 mg / kg of Angelica gigas extracts was 294.3 IU / L on average and decreased compared to OVX group, but there was no statistical significance.

The mean ALP in blood of the Angelica gigas extract 250mg / kg group was 249.5 IU / L on average and was significantly decreased (P <0.01) compared to the OVX group.

The mean ALP in blood of estradiol 30μg / kg group was 168.3 IU / L and it was statistically significant (P <0.01) compared with OVX group.

[Ca]

Ca in the blood of the Sham group showed an average of 9.5 mg / dL.

Ca in the blood of OVX group was 10.02mg / dL, which was statistically significant (p <0.01) compared with Sham group.

Ca in blood of 62.5mg / kg of Angelica gigas extract showed an average of 9.68mg / dL and was significantly decreased (p <0.01) compared with OVX group.

Ca in blood of 125 mg / kg of Angelica gigas extract showed an average of 9.67 mg / dL and was significantly decreased (p <0.01) compared to OVX group.

The Ca in blood of the Angelica gigas extract 250mg / kg treated group showed an average of 9.88mg / dL and there was no difference compared to the OVX group.

Ca in the blood of the estradiol 30μg / kg administration group showed an average of 9.92mg / dL and no difference compared to the OVX group.

[IP]

Phosphorus in the blood of the Sham group had an average of 6.22 mg / dL.

Blood phosphorus in the OVX group was 7.33 mg / dL, which was statistically significant (p <0.01) compared to the Sham group.

The mean phosphorus in the blood of the Angelica gigas extract 62.5mg / kg group showed an average of 7.37mg / dL and there was no difference compared to the OVX group.

The mean phosphorus in the blood of 125 mg / kg of Angelica gigas extract showed an average of 7.07 mg / dL and no difference compared to the OVX group.

The mean phosphorus in the blood of the Angelica gigas extract 250mg / kg showed an average of 7.15mg / dL and no difference compared to the OVX group.

The average phosphorus in blood of estradiol 30μg / kg group was 6.02mg / dL and it was statistically significant (P <0.01) compared with OVX group.

Osteocalcin

Osteocalcin in the blood of the Sham group was 22.48 ng / mL on average.

Osteocalcin in the blood of OVX group was 28.43ng / mL, which was statistically significant (p <0.01).

Osteocalcin in the blood of 62.5mg / kg of Angelica gigas extract showed an average of 28.16ng / mL and no difference compared to OVX group.

Osteocalcin in the blood of 125 mg / kg of Angelica gigas extract showed an average of 29.40 ng / mL and no difference compared to OVX group.

Osteocalcin in the blood of the Angelica gigas extract 250mg / kg showed an average of 24.49ng / mL and decreased compared with the OVX group, but there was no statistical difference.

Osteocalcin in the blood of the estradiol 30μg / kg group was 22.47 ng / mL on average and it was statistically significant (P <0.01) compared to the OVX group.

TABLE 2

[Biomarker Analysis Related to Urine Bone Health] (See Table 3 below)

[Deoxypyridinoline (DPD)]

DPD in the blood of the Sham group had an average of 614.37 nmol / L.

The mean DPD of the OVX group was 997.54 nmol / L, which was statistically significant (P <0.05) compared with the Sham group.

The mean DPD of 62.5 mg / kg of Angelica gigas extracts was 995.70 nmol / L and there was no difference compared to OVX group.

The mean DPD in the blood of 125 mg / kg of Angelica gigas extract was 358.91 nmol / L on average and was significantly decreased (p <0.01) compared with the OVX group.

The mean DPD in the blood of the Angelica gigas extract 250mg / kg was 897.15nmol / L on average and decreased compared with the OVX group, but there was no statistical significance.

Blood DPD of the estradiol 30μg / kg group showed an average of 491.5 nmol / L and was significantly decreased (P <0.01) compared with the OVX group.

[Type I Collagen cross-linked telopeptide (NTXⅠ)]

NTXI in the blood of the Sham group showed an average of 3.14 ng / mL.

NTXI in the blood of OVX group was 6.37ng / mL, which was statistically significant (p <0.05) compared with Sham group.

NTXⅠ in blood of 62.5 mg / kg of Angelica gigas extract showed an average of 4.49 ng / mL and decreased in comparison with OVX group but was not statistically significant.

NTXⅠ in the blood of 125mg / kg of Angelica gigas extract showed an average of 1.87ng / mL and was significantly decreased (p <0.01) compared with OVX group.

NTXⅠ in the blood of 250 mg / kg of Angelica gigas extract showed an average of 2.85 ng / mL and was significantly decreased (p <0.01) compared with the OVX group.

NTXⅠ in blood of estradiol 30μg / kg group showed an average of 3.64ng / mL and it was statistically significant (p <0.05) compared with OVX group.

TABLE 3

Femur Bone Mineral Density Analysis (see Table 4 below)

[Trabecular volume]

The volume of the cavernous bone of the Sham group was 3.03 mm ㅃ.

The mean volume of the cavernous bone of the OVX group was 0.30 mm ㅃ, which was statistically significant (p <0.01) compared with the Sham group.

The mean volume of spongy bone of femur of the Angelica gigas extract 62.5mg / kg was 0.53mm ㅃ and increased compared with OVX group, but it was not statistically significant.

The mean volume of spongy bone of femur in the Angelica gigas extract 125mg / kg was increased to 0.49mm 평균, and it was not statistically significant.

The mean volume of spongy bone of femur of the Angelica gigas extract 250mg / kg was 0.60mm ㅃ and increased compared with the OVX group, but it was not statistically significant.

The average volume of the cavernous bone of the estradiol 30μg / kg group was 0.63mm ㅃ and it was increased statistically (p <0.05) compared with the OVX group.

Bone Mineral Density (Trabecular BMD)

BMD of the cavernous bone of Sham group was 317.62mg / cm ㅃ.

The mean BMD of the cavernous bone of the OVX group was 25.96mg / cm ㅃ, which was statistically significant (p <0.01) compared with the Sham group.

The mean bone density of the cavernous bone of femoral cavernous extract, which was 62.5mg / kg, was increased to 45.23mg / cm3, but it was not statistically significant.

The mean BMD of the cavernous bones of the Angelica gigas extract 125mg / kg was average 41.64mg / cm ㅃ and increased compared with the OVX group, but it was not statistically significant.

The mean BMD of the cavernous bones of the Angelica gigas extract 250mg / kg showed an average of 47.45mg / cm ㅃ and increased compared with the OVX group, but it was not statistically significant.

The average BMD of the cavernous bone of the femoral bone of estradiol 30μg / kg group was 60.03mg / cm ㅃ and it was increased significantly (p <0.01).

Trabecular number (Tb. N; spongy bone number)

The number of spongy bones in the Sham group was 1.58 1 / mm on average.

The average number of spongy bones of the OVX group was 0.16 1 / mm, which was statistically significant (p <0.01) compared with the Sham group.

The average number of femur cavernous bones in the 62.5mg / kg alcohol extract group was 0.27 1 / mm and increased compared with the OVX group, but it was not statistically significant.

The mean number of femur cavernous bones in the 125mg / kg group of Angelica gigas extracts was 0.26 1 / mm on average and increased compared to the OVX group but was not statistically significant.

The mean number of spongy bones of femur in the Angelica gigas extract 250mg / kg was 0.26 1 / mm on average and it was not statistically significant.

The average number of spongy bones of femur in the estradiol 30μg / kg group was 0.38 1 / mm and it was increased statistically (p <0.01) compared with the OVX group.

[Trabecular thickness (Tb. Th; spongy bone thickness)]

The thickness of the cavernous bone of Sham group was 119.37μm.

The thickness of the cavernous bone of OVX group was 84.37μm on average, which was statistically significant (p <0.01) compared with Sham group.

The mean thickness of the femoral cavernous bone in the 62.5mg / kg group of Angelica gigas extract showed an average of 92.13μm and increased compared with the OVX group, but it was not statistically significant.

The mean thickness of the cavernous bone of the Angelica gigas extract 125mg / kg was average 91.08μm and increased compared to the OVX group, but it was not statistically significant.

The mean thickness of the cavernous bone of the Angelica gigas extract 250mg / kg was average 90.28μm and increased compared with the OVX group, but it was not statistically significant.

 The average thickness of the cavernous bone of the estradiol 30μg / kg group was 94.67μm and increased compared to the OVX group, but it was not statistically significant.

[Trabecular separation (Tb. Sp)]

The separation of the cavernous bone of the Sham group showed an average of 304.05 μm.

The separation of femur cavernous bone in OVX group was 276.88μm, which was decreased compared with Sham group, but it was not statistically significant.

The separation of femoral cavernous bone in the 62.5mg / kg group of Angelica gigas extract showed an average of 314.77μm and increased compared with the OVX group, but it was not statistically significant.

The separation of femoral cavernous bone in the 125mg / kg group of Angelica gigas extract showed an average of 351.65μm and increased compared with the OVX group, but it was not statistically significant.

The separation of femur cavernous bone in the control group of Angelica gigas extract 250mg / kg showed an average of 350.47μm and increased compared with the OVX group, but it was not statistically significant.

The separation of femoral cavernous bone in the estradiol 30μg / kg group showed an average of 345.63μm and was significantly (p <0.05) increased compared to the OVX group.

Structural model index (SMI)

The femoral SMI of the Sham group showed an average of 0.13.

The mean femoral SMI of the OVX group was 0.47, which was statistically significant (p <0.01) compared with the Sham group.

The mean femoral SMI of 62.5mg / kg of Angelica gigas extract was decreased to 0.31 on average, but it was not statistically significant.

The mean femoral SMI of 125mg / kg of Angelica gigas extracts was 0.33 on average and decreased compared to OVX group, but was not statistically significant.

The mean femoral SMI of the Angelica gigas extract 250mg / kg group was 0.33 on average and increased compared to the OVX group but was not statistically significant.

The average femoral SMI of estradiol 30μg / kg group was 0.30 and it was significantly increased (p <0.01) compared with OVX group.

[Connectivity density (Conn. D)]

Femur of Sham County Conn. D showed an average of 34.94 1 / mm ㅃ.

Femoral conn. The mean D was 1.43 1 / mm ㅃ, which was statistically significant (p <0.01) compared with the Sham group.

Femur Conn. Of Angelica gigas extract 62.5 mg / kg. The mean D was 3.74 1 / mm ㅃ and increased compared to the OVX group but was not statistically significant.

Femur Conn. Of Angelica gigas extract 125 mg / kg. The mean D was 2.96 1 / mm 었으며 and increased compared to the OVX group, but it was not statistically significant.

 Femoral Conn. The mean D was 3.20 1 / mm3 and increased compared to the OVX group but was not statistically significant.

Estradiol femoral Conn. D showed an average of 4.76 1 / mm ㅃ and was significantly increased (p <0.01) compared with OVX group.

Bone surface (BS)

The average femoral bone area of Sham group was 97.28mm28.

The average femoral bone area of the OVX group was 14.17 mm ㅂ, which was statistically significant (p <0.01) compared with the Sham group.

The average femoral bone area of 62.5mg / kg of Angelica gigas extract was increased to 23.52 mm ㅂ and it was not statistically significant.

The average femoral bone area of the Angelica gigas extract 125mg / kg group was 21.39 mm ㅂ and increased compared with the OVX group, but it was not statistically significant.

The average femoral bone area of the Angelica gigas extract 250mg / kg group was 26.02 mm ㅂ and increased compared with the OVX group, but it was not statistically significant.

The average femoral bone area of the estradiol 30μg / kg group was 26.31mm ㅂ and it was statistically significant (p <0.05) compared with the OVX group.

[Bone volume fraction (Bone volume / Total volume; BV / TV)]

The femoral BV / TV of the Sham group was 18.72% on average.

The average femoral BV / TV of the OVX group was 1.57%, which was statistically significant (p <0.01) compared to the Sham group.

The average femoral BV / TV of 62.5mg / kg of Angelica gigas extract was increased by 2.70%, which was higher than the OVX group, but it was not statistically significant.

The average femoral BV / TV of 125mg / kg of Angelica gigas extract was increased by 2.48%, but it was not statistically significant.

The average femoral BV / TV of 250mg / kg of Angelica gigas extract was increased by 2.85%, but it was not statistically significant.

The average femoral BV / TV of estradiol 30μg / kg group was 3.59% and it was statistically significant (p <0.01) compared with OVX group.

TABLE 4

Analysis of estradiol concentration in blood (see Table 5 below)

The concentration of estradiol in the blood of the Sham group was 127.32 pg / mL.

The mean concentration of estradiol in the blood of the OVX group was 44.29 pg / mL, which was statistically significant (p <0.01) compared with the Sham group.

The concentration of estradiol in the blood of 62.5mg / kg of Angelica gigas extract was 28.18 pg / mL, which was decreased compared with OVX group, but it was not statistically significant.

The mean concentration of estradiol in the blood of 125 mg / kg of Angelica gigas extract was increased to 55.05 pg / mL and was not statistically significant.

The mean concentration of estradiol in the blood of 250 mg / kg of Angelica gigas extracts was 62.27 pg / mL, which was statistically significant (p <0.01) compared to the OVX group.

The estradiol concentration in the blood of the estradiol 30μg / kg group was 31.02 pg / mL, which was statistically significant (p <0.01) compared with the OVX group.

TABLE 5

Claims (2)

As a method of administering the Angelica gigas extract, administration method characterized in that oral administration of the Angelica gigas extract 62.5 ~ 250mg / kg. The method of claim 1, wherein the administration is performed once a day.

Images